[J01EC01, sulfamethoxazole, The metabolism of Alfuzosin can be decreased when combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Sulpiride.]
[L02BA01, tamoxifen, The metabolism of Alfuzosin can be decreased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Alfuzosin can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Alfuzosin.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Tetrabenazine.]
[S03AA02, tetracycline, The metabolism of Alfuzosin can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, Lurasidone may increase the hypotensive activities of Alfuzosin.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Apomorphine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Eribulin.]
[N05CA19, thiopental, The metabolism of Alfuzosin can be decreased when combined with Thiopental.]
[N05AB08, thioproperazine, Thioproperazine may increase the hypotensive activities of Alfuzosin.]
[N05AC02, thioridazine, Thioridazine may increase the hypotensive activities of Alfuzosin.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Thiothixene.]
[G04BE06, moxisylyte, Moxisylyte may increase the hypotensive activities of Alfuzosin.]
[S01ED01, timolol, Alfuzosin may increase the hypotensive activities of Timolol.]
[M02AX02, tolazoline, Tolazoline may increase the hypotensive activities of Alfuzosin.]
[N06AF04, tranylcypromine, The metabolism of Alfuzosin can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Alfuzosin.]
[C03AA06, trichlormethiazide, Alfuzosin may increase the hypotensive activities of Trichlormethiazide.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the hypotensive activities of Alfuzosin.]
[A03AA05, trimebutine, The risk or severity of hypotension can be increased when Alfuzosin is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Alfuzosin is combined with Trimethadione.]
[C02BA01, trimethaphan, Alfuzosin may increase the hypotensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the hypotensive activities of Alfuzosin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Triprolidine.]
[J01FA08, troleandomycin, The metabolism of Alfuzosin can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, Alfuzosin may increase the hypotensive activities of Azilsartan medoxomil.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Alfuzosin can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Alfuzosin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Alfuzosin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Alfuzosin can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Alfuzosin can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ezogabine.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Alfuzosin.]
[B01AC24, ticagrelor, The metabolism of Alfuzosin can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, Verapamil may increase the hypotensive activities of Alfuzosin.]
[N06AX09, viloxazine, The metabolism of Alfuzosin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Alfuzosin can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Alfuzosin may increase the hypotensive activities of Vincamine.]
[C03BA10, xipamide, Alfuzosin may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the hypotensive activities of Alfuzosin.]
[J05AE02, indinavir, The metabolism of Alfuzosin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Alfuzosin.]
[L01FX05, brentuximab vedotin, The metabolism of Alfuzosin can be decreased when combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Alfuzosin can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Alfuzosin can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Alfuzosin can be decreased when combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Tolterodine.]
[C07AB03, atenolol, Alfuzosin may increase the hypotensive activities of Atenolol.]
[J02AC03, voriconazole, The metabolism of Alfuzosin can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Atropine.]
[R07AX02, ivacaftor, The metabolism of Alfuzosin can be decreased when combined with Ivacaftor.]
[G04BE10, avanafil, Alfuzosin may increase the hypotensive activities of Avanafil.]
[G04BD12, mirabegron, The therapeutic efficacy of Mirabegron can be decreased when used in combination with Alfuzosin.]
[V03AX03, cobicistat, The metabolism of Alfuzosin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Alfuzosin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Alfuzosin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Alfuzosin can be decreased when combined with Bosutinib.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Alfuzosin.]
[L01EX05, regorafenib, The metabolism of Alfuzosin can be decreased when combined with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Alfuzosin can be decreased when combined with Nelfinavir.]
[C08CA13, lercanidipine, Alfuzosin may increase the hypotensive activities of Lercanidipine.]
[H01CB05, pasireotide, The metabolism of Alfuzosin can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Alfuzosin.]
[C10AX12, lomitapide, The metabolism of Alfuzosin can be decreased when combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Alfuzosin is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, Alfuzosin may increase the hypotensive activities of Bendroflumethiazide.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Moxifloxacin.]
[L04AA18, everolimus, The metabolism of Alfuzosin can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Alfuzosin.]
[L01EC02, dabrafenib, The metabolism of Alfuzosin can be decreased when combined with Dabrafenib.]
[C08EA02, bepridil, Alfuzosin may increase the hypotensive activities of Bepridil.]
[C02KX05, riociguat, Alfuzosin may increase the hypotensive activities of Riociguat.]
[C02KX04, macitentan, Alfuzosin may increase the hypotensive activities of Macitentan.]
[J05AP05, simeprevir, The metabolism of Alfuzosin can be decreased when combined with Simeprevir.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Alfuzosin.]
[C07AB04, acebutolol, Alfuzosin may increase the hypotensive activities of Acebutolol.]
[A16AA07, metreleptin, The metabolism of Alfuzosin can be increased when combined with Metreleptin.]
[S01ED02, betaxolol, Alfuzosin may increase the hypotensive activities of Betaxolol.]
[C02CC01, bethanidine, Alfuzosin may increase the hypotensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Alfuzosin can be decreased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Alfuzosin can be decreased when combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Hyoscyamine.]
[L01EM01, idelalisib, The metabolism of Alfuzosin can be decreased when combined with Idelalisib.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Alfuzosin.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Eliglustat.]
[N05AA04, acepromazine, Acepromazine may increase the hypotensive activities of Alfuzosin.]
[L01XK01, olaparib, The metabolism of Alfuzosin can be decreased when combined with Olaparib.]
[N06AX11, mirtazapine, Mirtazapine may increase the hypotensive activities of Alfuzosin.]
[L01EF01, palbociclib, The metabolism of Alfuzosin can be decreased when combined with Palbociclib.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Alfuzosin can be decreased when combined with Acetaminophen.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ivabradine.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the hypotensive activities of Alfuzosin.]
[S01EC01, acetazolamide, The metabolism of Alfuzosin can be decreased when combined with Acetazolamide.]
[A02BC03, lansoprazole, The metabolism of Alfuzosin can be decreased when combined with Lansoprazole.]
[J02AC05, isavuconazole, The metabolism of Alfuzosin can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Alfuzosin may increase the hypotensive activities of Selexipag.]
[S01AA13, fusidic acid, The metabolism of Alfuzosin can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Pipemidic acid.]
[J05AP10, elbasvir, The metabolism of Alfuzosin can be decreased when combined with Elbasvir.]
[L01XX52, venetoclax, The metabolism of Alfuzosin can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, Bromocriptine may increase the hypotensive activities of Alfuzosin.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dexbrompheniramine.]
[C08CA01, amlodipine, Alfuzosin may increase the hypotensive activities of Amlodipine.]
[C07AA19, bupranolol, Alfuzosin may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Alfuzosin can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Buserelin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Alfuzosin can be decreased when combined with Rabeprazole.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Azatadine.]
[S01GX07, azelastine, The metabolism of Alfuzosin can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Alfuzosin can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Alfuzosin can be decreased when combined with Ribociclib.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Alfuzosin.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Alfuzosin.]
[C09AA07, benazepril, Alfuzosin may increase the hypotensive activities of Benazepril.]
[J05AE09, tipranavir, The metabolism of Alfuzosin can be decreased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Alfuzosin can be decreased when combined with Midostaurin.]
[L04AC14, sarilumab, The metabolism of Alfuzosin can be decreased when combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Delafloxacin.]
[D01AC10, bifonazole, The metabolism of Alfuzosin can be decreased when combined with Bifonazole.]
[L01XX59, enasidenib, The metabolism of Alfuzosin can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Vorinostat.]
[C07AB07, bisoprolol, Alfuzosin may increase the hypotensive activities of Bisoprolol.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Alfuzosin.]
[J05AG03, efavirenz, The metabolism of Alfuzosin can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may increase the orthostatic hypotensive activities of Alfuzosin.]
[C04AX20, buflomedil, Buflomedil may increase the hypotensive activities of Alfuzosin.]
[L01EL02, acalabrutinib, The metabolism of Alfuzosin can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Alfuzosin can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The metabolism of Alfuzosin can be decreased when combined with Capsaicin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Acrivastine.]
[C09AA01, captopril, Alfuzosin may increase the hypotensive activities of Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Alfuzosin can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Alfuzosin can be increased when combined with Carbamazepine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Carbinoxamine.]
[C07AG02, carvedilol, Carvedilol may increase the hypotensive activities of Alfuzosin.]
[B02BX09, fostamatinib, The metabolism of Alfuzosin can be decreased when combined with Fostamatinib.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Encorafenib.]
[C07AB08, celiprolol, Alfuzosin may increase the hypotensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Alfuzosin can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Alfuzosin can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Alfuzosin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Inotersen.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Cibenzoline.]
[C09AA08, cilazapril, Alfuzosin may increase the hypotensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Alfuzosin can be decreased when combined with Triclabendazole.]
[J01FA09, clarithromycin, The metabolism of Alfuzosin can be decreased when combined with Clarithromycin.]
[C09CA06, candesartan, Alfuzosin may increase the hypotensive activities of Candesartan.]
[L01EM03, alpelisib, The metabolism of Alfuzosin can be decreased when combined with Alpelisib.]
[C03BX03, cicletanine, Alfuzosin may increase the hypotensive activities of Cicletanine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Alfuzosin can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Alfuzosin.]
[C03AA09, cyclothiazide, Alfuzosin may increase the hypotensive activities of Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may increase the hypotensive activities of Alfuzosin.]
[S01EX02, dapiprazole, Dapiprazole may increase the hypotensive activities of Alfuzosin.]
[N03AX25, cenobamate, The metabolism of Alfuzosin can be decreased when combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dexchlorpheniramine.]
[J05AB16, remdesivir, The metabolism of Alfuzosin can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Alfuzosin can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Alfuzosin can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, Dutasteride may increase the hypotensive activities of Alfuzosin.]
[C08CA16, clevidipine, The metabolism of Alfuzosin can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, Dronedarone may increase the hypotensive activities of Alfuzosin.]
[J01FA13, dirithromycin, The metabolism of Alfuzosin can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Alfuzosin can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Chlorcyclizine.]
[C02AA06, methoserpidine, Alfuzosin may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Alfuzosin.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Alfuzosin.]
[C08CA17, levamlodipine, Alfuzosin may increase the hypotensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Fostemsavir.]
[L04AC19, satralizumab, The serum concentration of Alfuzosin can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Alfuzosin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Alfuzosin may increase the hypotensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the hypotensive activities of Alfuzosin.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Alfuzosin may increase the hypotensive activities of Chlorthalidone.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Alfuzosin is combined with Vinpocetine.]
[B06AC06, berotralstat, The metabolism of Alfuzosin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Alfuzosin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Relugolix.]
[P03AX07, abametapir, The serum concentration of Alfuzosin can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Felbamate.]
[C01CA19, fenoldopam, Alfuzosin may increase the hypotensive activities of Fenoldopam.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Flumequine.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Alfuzosin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Alfuzosin.]
[H04AA02, dasiglucagon, Alfuzosin may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Alfuzosin can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Alfuzosin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Alfuzosin can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Alfuzosin can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The metabolism of Alfuzosin can be decreased when combined with Citalopram.]
[P01CA03, fexinidazole, The metabolism of Alfuzosin can be decreased when combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Clemastine.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Alfuzosin.]
[N06AX25, St. John's wort extract, The metabolism of Alfuzosin can be increased when combined with St. John's Wort.]
[J04BA01, clofazimine, The metabolism of Alfuzosin can be decreased when combined with Clofazimine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Clomipramine.]
[S01EA04, clonidine, Alfuzosin may increase the hypotensive activities of Clonidine.]
[C01EB24, mavacamten, The serum concentration of Alfuzosin can be decreased when it is combined with Mavacamten.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Granisetron.]
[N05AH02, clozapine, Clozapine may increase the hypotensive activities of Alfuzosin.]
[H01AC08, somatrogon, The metabolism of Alfuzosin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Cocaine.]
[C02KB01, metyrosine, Alfuzosin may increase the hypotensive activities of Metyrosine.]
[M04AC01, colchicine, The metabolism of Alfuzosin can be decreased when combined with Colchicine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Desflurane.]
[C04AX28, ifenprodil, Ifenprodil may increase the hypotensive activities of Alfuzosin.]
[J01FA15, telithromycin, The metabolism of Alfuzosin can be decreased when combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Desloratadine.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Alfuzosin.]
[J02AC02, itraconazole, The metabolism of Alfuzosin can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Alfuzosin can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The metabolism of Alfuzosin can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Alfuzosin can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Alfuzosin may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Levocabastine.]
[N07BC04, lofexidine, Alfuzosin may increase the hypotensive activities of Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Lomefloxacin.]
[C09AA03, lisinopril, Alfuzosin may increase the hypotensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Alfuzosin can be decreased when combined with Manidipine.]
[C07AA14, mepindolol, Mepindolol may increase the orthostatic hypotensive activities of Alfuzosin.]
[R06AD07, mequitazine, The metabolism of Alfuzosin can be decreased when combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Adenosine.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Alfuzosin is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Cyclizine.]
[C03DA04, eplerenone, Alfuzosin may increase the hypotensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Melperone.]
[C03AA07, cyclopenthiazide, Alfuzosin may increase the hypotensive activities of Cyclopenthiazide.]
[J01FA03, midecamycin, The metabolism of Alfuzosin can be decreased when combined with Midecamycin.]
[S01XA18, cyclosporine, The metabolism of Alfuzosin can be decreased when combined with Cyclosporine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Cyproheptadine.]
[C09AA13, moexipril, Alfuzosin may increase the hypotensive activities of Moexipril.]
[C03XA02, conivaptan, The metabolism of Alfuzosin can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Alfuzosin may increase the hypotensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Alfuzosin.]
[M01AH05, etoricoxib, The metabolism of Alfuzosin can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Alfuzosin can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The metabolism of Alfuzosin can be decreased when combined with Daunorubicin.]
[C02CC04, debrisoquin, Alfuzosin may increase the hypotensive activities of Debrisoquine.]
[C07AB12, nebivolol, Alfuzosin may increase the hypotensive activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Alfuzosin can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Alfuzosin may increase the hypotensive activities of Nicorandil.]
[C01CA23, theodrenaline, Alfuzosin may decrease the hypertensive activities of Theodrenaline.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Alfuzosin.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Solifenacin.]
[N06AA01, desipramine, The metabolism of Alfuzosin can be decreased when combined with Desipramine.]
[C09XA02, aliskiren, Alfuzosin may increase the hypotensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxaliplatin.]
[N03AF02, oxcarbazepine, The metabolism of Alfuzosin can be decreased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Alfuzosin can be decreased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Alfuzosin can be decreased when combined with Oxybutynin.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Amphetamine.]
[N06AB05, paroxetine, The metabolism of Alfuzosin can be decreased when combined with Paroxetine.]
[A03AX15, peppermint oil, The metabolism of Alfuzosin can be decreased when combined with Peppermint oil.]
[N05BA01, diazepam, The metabolism of Alfuzosin can be decreased when combined with Diazepam.]
[V03AH01, diazoxide, Alfuzosin may increase the hypotensive activities of Diazoxide.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Foscarnet.]
[C02DG01, pinacidil, Alfuzosin may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Alfuzosin is combined with Pinaverium.]
[L01EB02, erlotinib, The metabolism of Alfuzosin can be decreased when combined with Erlotinib.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Alfuzosin.]
[A08AA03, diethylpropion, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Alfuzosin can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Alfuzosin can be decreased when combined with Isradipine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Digoxin.]
[C02DB01, dihydralazine, Alfuzosin may increase the hypotensive activities of Dihydralazine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypotensive activities of Alfuzosin.]
[J05AE08, atazanavir, The metabolism of Alfuzosin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Alfuzosin may increase the hypotensive activities of Treprostinil.]
[C08DB01, diltiazem, The metabolism of Alfuzosin can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dimenhydrinate.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Alfuzosin.]
[M02AX03, dimethyl sulfoxide, The metabolism of Alfuzosin can be decreased when combined with Dimethyl sulfoxide.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Diphenhydramine.]
[C09AA06, quinapril, Alfuzosin may increase the hypotensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Alfuzosin.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Cisapride.]
[C09AA05, ramipril, Alfuzosin may increase the hypotensive activities of Ramipril.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Alfuzosin.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Alfuzosin can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Alfuzosin can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Risperidone may increase the hypotensive activities of Alfuzosin.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Levocetirizine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Alfuzosin can be decreased when combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Alfuzosin can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Alfuzosin.]
[G04BE08, tadalafil, Alfuzosin may increase the hypotensive activities of Tadalafil.]
[C02KX02, ambrisentan, Alfuzosin may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Alfuzosin can be decreased when combined with Ranolazine.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Alfuzosin.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Alfuzosin.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dosulepin.]
[N06AA12, doxepin, Doxepin may increase the hypotensive activities of Alfuzosin.]
[L01DB01, doxorubicin, The metabolism of Alfuzosin can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Doxylamine.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the hypotensive activities of Alfuzosin.]
[C09AA11, spirapril, Alfuzosin may increase the hypotensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Sultopride.]
[G01AF05, econazole, The metabolism of Alfuzosin can be decreased when combined with Econazole.]
[C07AB13, talinolol, Alfuzosin may increase the hypotensive activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Temafloxacin.]
[G04CA03, terazosin, Terazosin may increase the hypotensive activities of Alfuzosin.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Alfuzosin is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may increase the orthostatic hypotensive activities of Alfuzosin.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Alfuzosin.]
[C09AA02, enalapril, Alfuzosin may increase the hypotensive activities of Enalapril.]
[G01AF08, tioconazole, The metabolism of Alfuzosin can be decreased when combined with Tioconazole.]
[N05BA23, tofisopam, The metabolism of Alfuzosin can be decreased when combined with Tofisopam.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Alfuzosin.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Toremifene.]
[C03CA04, torsemide, Alfuzosin may increase the hypotensive activities of Torasemide.]
[C09AA10, trandolapril, Alfuzosin may increase the hypotensive activities of Trandolapril.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Triptorelin.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Alfuzosin.]
[C02CA06, urapidil, Urapidil may increase the hypotensive activities of Alfuzosin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Enoxacin.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Alfuzosin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Epinastine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Alfuzosin.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Alfuzosin.]
[C08CA12, mepirodipine, The metabolism of Alfuzosin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Alfuzosin can be decreased when combined with Epinephrine.]
[C09AA15, zofenopril, Alfuzosin may increase the hypotensive activities of Zofenopril.]
[N03AX15, zonisamide, The risk or severity of hypotension can be increased when Alfuzosin is combined with Zonisamide.]
[C02AC02, guanfacine, Alfuzosin may increase the hypotensive activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Moricizine.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Alfuzosin.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypotensive activities of Alfuzosin.]
[N02CA02, ergotamine, The metabolism of Alfuzosin can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Alfuzosin can be decreased when combined with Erythromycin.]
[R03BA09, fluticasone furoate, The metabolism of Alfuzosin can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Alfuzosin can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Alfuzosin can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Gepefrine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Alfuzosin is combined with Ethosuximide.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Alfuzosin.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Alfuzosin.]
[L01CB01, etoposide, The metabolism of Alfuzosin can be decreased when combined with Etoposide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ajmaline.]
[L04AD02, tacrolimus, The metabolism of Alfuzosin can be decreased when combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Alfuzosin can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Alfuzosin can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Alfuzosin can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Famotidine.]
[C08CA02, felodipine, Alfuzosin may increase the hypotensive activities of Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Alfuzosin is combined with Fendiline.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Alfuzosin.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Alfuzosin.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Flecainide.]
[J02AC01, fluconazole, The metabolism of Alfuzosin can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Alfuzosin is combined with Flunarizine.]
[V03AZ01, ethanol, The metabolism of Alfuzosin can be decreased when combined with Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Alfuzosin.]
[N05AF01, flupenthixol, Flupentixol may increase the hypotensive activities of Alfuzosin.]
[N05AG01, fluspirilene, The risk or severity of hypotension can be increased when Alfuzosin is combined with Fluspirilene.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Alfuzosin.]
[J05AE10, darunavir, The risk or severity of hypotension can be increased when Darunavir is combined with Alfuzosin.]
[C03CA01, furosemide, Alfuzosin may increase the hypotensive activities of Furosemide.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Galantamine.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Alfuzosin is combined with Gallopamil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Alfuzosin can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The metabolism of Alfuzosin can be decreased when combined with Cabergoline.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Alfuzosin is combined with Methsuximide.]
[L01EH01, lapatinib, The metabolism of Alfuzosin can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Alfuzosin can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Alfuzosin.]
[C05AE01, nitroglycerin, Alfuzosin may increase the hypotensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dofetilide.]
[C02CA04, doxazosin, Doxazosin may increase the hypotensive activities of Alfuzosin.]
[L01EX02, sorafenib, The metabolism of Alfuzosin can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Alfuzosin may increase the hypotensive activities of Esmolol.]
[C09AA09, fosinopril, Alfuzosin may increase the hypotensive activities of Fosinopril.]
[S01EX01, guanethidine, Alfuzosin may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Halofantrine.]
[N05AD01, haloperidol, The metabolism of Alfuzosin can be decreased when combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Histrelin.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Alfuzosin.]
[C09CA01, losartan, The metabolism of Alfuzosin can be decreased when combined with Losartan.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Alfuzosin.]
[C08CA10, nilvadipine, The metabolism of Alfuzosin can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Alfuzosin is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxatomide.]
[C09AA04, perindopril, Alfuzosin may increase the hypotensive activities of Perindopril.]
[C02DB02, hydralazine, The metabolism of Alfuzosin can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, Alfuzosin may increase the hypotensive activities of Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, Alfuzosin may increase the hypotensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Propiverine may increase the hypotensive activities of Alfuzosin.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Hydroxyzine.]
[C02AC06, rilmenidine, Alfuzosin may increase the hypotensive activities of Rilmenidine.]
[L01AA06, ifosfamide, The metabolism of Alfuzosin can be decreased when combined with Ifosfamide.]
[N06AA02, imipramine, Imipramine may increase the hypotensive activities of Alfuzosin.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Terlipressin.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Alfuzosin.]
[L01CE01, topotecan, The metabolism of Alfuzosin can be decreased when combined with Topotecan.]
[C03BA11, indapamide, Alfuzosin may increase the hypotensive activities of Indapamide.]
[C02CA02, indoramin, Indoramin may increase the hypotensive activities of Alfuzosin.]
[N06AX17, milnacipran, The metabolism of Alfuzosin can be decreased when combined with Milnacipran.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Buclizine.]
[C10AA06, cerivastatin, The metabolism of Alfuzosin can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Anagrelide.]
[C07AA01, alprenolol, Alfuzosin may increase the hypotensive activities of Alprenolol.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Alfuzosin.]
[C09AA16, imidapril, Alfuzosin may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Isoflurane.]
[J04AC01, isoniazid, The metabolism of Alfuzosin can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Alfuzosin.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Alfuzosin.]
[C02KD01, ketanserin, Alfuzosin may increase the hypotensive activities of Ketanserin.]
[H02CA04, levoketoconazole, The metabolism of Alfuzosin can be decreased when combined with Levoketoconazole.]
[J02AB02, ketoconazole, The metabolism of Alfuzosin can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the hypotensive activities of Alfuzosin.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Mizolastine.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Alfuzosin.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Nalidixic acid.]
[C07AG01, labetalol, Labetalol may increase the hypotensive activities of Alfuzosin.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Amantadine.]
[C02AA05, deserpidine, Alfuzosin may increase the hypotensive activities of Deserpidine.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Alfuzosin is combined with Lidoflazine.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Alfuzosin is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Alfuzosin can be decreased when combined with Lovastatin.]
[V04CC02, magnesium sulfate, The risk or severity of hypotension can be increased when Alfuzosin is combined with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Alfuzosin can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Maprotiline.]
[C02BB01, mecamylamine, Alfuzosin may increase the hypotensive activities of Mecamylamine.]
[P01BC02, mefloquine, The metabolism of Alfuzosin can be decreased when combined with Mefloquine.]
[C01CA11, mephentermine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Mephentermine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Mesoridazine.]
[N05AX13, paliperidone, Paliperidone may increase the hypotensive activities of Alfuzosin.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Alfuzosin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dolasetron.]
[H01CB03, lanreotide, The metabolism of Alfuzosin can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Alfuzosin can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Metamfetamine.]
[H03BB02, methimazole, The metabolism of Alfuzosin can be decreased when combined with Methimazole.]
[N02BG08, ziconotide, The risk or severity of hypotension can be increased when Alfuzosin is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the hypotensive activities of Alfuzosin.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Alfuzosin.]
[C02AB01, methyldopa, Alfuzosin may increase the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, The metabolism of Alfuzosin can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Alfuzosin can be decreased when combined with Methylergometrine.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Metoclopramide.]
[C03BA08, metolazone, Alfuzosin may increase the hypotensive activities of Metolazone.]
[C07AB02, metoprolol, Alfuzosin may increase the hypotensive activities of Metoprolol.]
[P01AB01, metronidazole, The metabolism of Alfuzosin can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Alfuzosin can be decreased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Alfuzosin can be decreased when combined with Miconazole.]
[N05CD08, midazolam, The metabolism of Alfuzosin can be decreased when combined with Midazolam.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Alfuzosin.]
[G03XB01, mifepristone, The metabolism of Alfuzosin can be decreased when combined with Mifepristone.]
[C09CA03, valsartan, Alfuzosin may increase the hypotensive activities of Valsartan.]
[D11AX01, minoxidil, Alfuzosin may increase the hypotensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Alfuzosin can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Lisdexamfetamine.]
[L03AC01, aldesleukin, The metabolism of Alfuzosin can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Alfuzosin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the hypotensive activities of Alfuzosin.]
[L01EX03, pazopanib, The metabolism of Alfuzosin can be decreased when combined with Pazopanib.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Amodiaquine.]
[G04CA04, silodosin, Silodosin may increase the hypotensive activities of Alfuzosin.]
[G03XC01, raloxifene, The metabolism of Alfuzosin can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may increase the hypotensive activities of Alfuzosin.]
[N03AB05, fosphenytoin, The metabolism of Alfuzosin can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Alfuzosin may increase the hypotensive activities of Nadolol.]
[V03AB15, naloxone, The metabolism of Alfuzosin can be decreased when combined with Naloxone.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Alfuzosin.]
[N06BA01, amphetamine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Amphetamine.]
[L01CD02, docetaxel, The metabolism of Alfuzosin can be decreased when combined with Docetaxel.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Levosimendan.]
[N05AX14, iloperidone, Iloperidone may increase the hypotensive activities of Alfuzosin.]
[N06AX23, desvenlafaxine, The metabolism of Alfuzosin can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Alfuzosin may increase the hypotensive activities of Telmisartan.]
[C08CA04, nicardipine, Nicardipine may increase the hypotensive activities of Alfuzosin.]
[C04AE02, nicergoline, Nicergoline may increase the hypotensive activities of Alfuzosin.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Alfuzosin is combined with Nifedipine.]
[C08CA06, nimodipine, Alfuzosin may increase the hypotensive activities of Nimodipine.]
[C08CA07, nisoldipine, Alfuzosin may increase the hypotensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Alfuzosin may increase the hypotensive activities of Nitrendipine.]
[R07AX01, nitric oxide, The metabolism of Alfuzosin can be decreased when combined with Nitric Oxide.]
[C02DD01, nitroprusside, Alfuzosin may increase the hypotensive activities of Nitroprusside.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Alfuzosin.]
[S01AE02, norfloxacin, The metabolism of Alfuzosin can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, Alfuzosin may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the hypotensive activities of Alfuzosin.]
[R05DA07, noscapine, The metabolism of Alfuzosin can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Alfuzosin.]
[H01CB02, octreotide, The metabolism of Alfuzosin can be decreased when combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ofloxacin.]
[J01FA05, oleandomycin, The metabolism of Alfuzosin can be decreased when combined with Oleandomycin.]
[A02BC01, omeprazole, The metabolism of Alfuzosin can be decreased when combined with Omeprazole.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Alfuzosin.]
[G04CA02, tamsulosin, Tamsulosin may increase the hypotensive activities of Alfuzosin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Alfuzosin may increase the hypotensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Alfuzosin.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Alfuzosin.]
[A14AA05, oxymetholone, The metabolism of Alfuzosin can be decreased when combined with Oxymetholone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alfuzosin.]
[N05AH05, asenapine, Asenapine may increase the hypotensive activities of Alfuzosin.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Papaverine.]
[H02AB05, paramethasone, The metabolism of Alfuzosin can be decreased when combined with Paramethasone.]
[C02KC01, pargyline, Alfuzosin may increase the hypotensive activities of Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Pefloxacin.]
[C07AA23, penbutolol, Alfuzosin may increase the hypotensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypotension can be increased when Alfuzosin is combined with Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Alfuzosin can be increased when combined with Pentobarbital.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Alfuzosin.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Alfuzosin is combined with Perhexiline.]
[N06AF03, phenelzine, The metabolism of Alfuzosin can be decreased when combined with Phenelzine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Alfuzosin can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may increase the hypotensive activities of Alfuzosin.]
[A08AA01, phentermine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Phentolamine may increase the hypotensive activities of Alfuzosin.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Alfuzosin.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Alfuzosin.]
[N03AB02, phenytoin, The metabolism of Alfuzosin can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Alfuzosin can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The metabolism of Alfuzosin can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Alfuzosin can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Alfuzosin can be decreased when combined with Pimozide.]
[C07AA03, pindolol, Alfuzosin may increase the hypotensive activities of Pindolol.]
[J05AE01, saquinavir, The metabolism of Alfuzosin can be decreased when combined with Saquinavir.]
[C09CA02, eprosartan, Alfuzosin may increase the hypotensive activities of Eprosartan.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Grepafloxacin.]
[N02CX01, pizotyline, Pizotifen may increase the hypotensive activities of Alfuzosin.]
[J05AG02, delavirdine, The metabolism of Alfuzosin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Alfuzosin can be decreased when combined with Irbesartan.]
[C03AA05, polythiazide, Alfuzosin may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, Alfuzosin may increase the hypotensive activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Prajmaline.]
[C02CA01, prazosin, Prazosin may increase the hypotensive activities of Alfuzosin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Alfuzosin is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Alfuzosin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Alfuzosin can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Procainamide.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Prochlorperazine.]
[N05AA03, promazine, Promazine may increase the hypotensive activities of Alfuzosin.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Promethazine.]
[C01BC03, propafenone, Propafenone may increase the orthostatic hypotensive activities of Alfuzosin.]
[N05AC01, periciazine, Periciazine may increase the hypotensive activities of Alfuzosin.]
[N05CM06, propiomazine, Propiomazine may increase the hypotensive activities of Alfuzosin.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Romidepsin.]
[N01AX10, propofol, The metabolism of Alfuzosin can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Alfuzosin can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Alfuzosin may increase the hypotensive activities of Propranolol.]
[B01AC09, epoprostenol, Alfuzosin may increase the hypotensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Alfuzosin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Alfuzosin.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the hypotensive activities of Alfuzosin.]
[P01BC01, quinine, The metabolism of Alfuzosin can be decreased when combined with Quinine.]
[C02AA01, rescinnamine, Alfuzosin may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, Alfuzosin may increase the hypotensive activities of Reserpine.]
[J04AB02, rifampin, The metabolism of Alfuzosin can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Alfuzosin.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Alfuzosin.]
[J01FA06, roxithromycin, The metabolism of Alfuzosin can be decreased when combined with Roxithromycin.]
[C05CA01, rutin, The metabolism of Alfuzosin can be decreased when combined with Rutin.]
[H01CB01, somatostatin, The metabolism of Alfuzosin can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, Sotalol may increase the orthostatic hypotensive activities of Alfuzosin.]
[N03AG01, valproic acid, The metabolism of Alfuzosin can be decreased when combined with Valproic acid.]
